All In Biotech

Drug Trial Radar · NCT05405166

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 531 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

531

Actual

Start

Jun 23, 2022

Primary completion

Nov 6, 2024

Study completion Oct 22, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who will receive at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants were randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants are allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.

Conditions

  • Plasma Cell Myeloma Recurrent

Interventions

  • Isatuximab IVDrug

    Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous

  • Isatuximab SCDrug

    Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)

  • DexamethasoneDrug

    Pharmaceutical form: Tablet; Route of administration: Oral

  • PomalidomideDrug

    Pharmaceutical form: hard capsules; Route of administration: Oral

  • DexamethasoneDrug

    Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02

  • MontelukastDrug

    Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03

  • Paracetamol / AcetaminophenDrug

    Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01

  • DiphenhydramineDrug

    Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02

  • MethylprednisoloneDrug

    Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
  2. Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady StateTime frame: Pre-dose at Cycle 6 Day 1

Locations

128 sites in 21 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers - Aurora- Site Number : 8400021

    Aurora, Colorado

  • Mayo Clinic in Florida- Site Number : 8400008

    Jacksonville, Florida

  • Boca Raton Clinical Research Associates- Site Number : 8400030

    Plantation, Florida

  • Hattiesburg Clinic- Site Number : 8400006

    Hattiesburg, Mississippi

  • Atlantic Health System- Site Number : 8400005

    Morristown, New Jersey

  • New York Oncology Hematology - Albany Cancer Center- Site Number : 8400017

    Albany, New York

  • Novant Health Neurology & Sleep- Site Number : 8400014

    Charlotte, North Carolina

  • Gabrail Cancer Center- Site Number : 8400027

    Canton, Ohio

  • Oncology Hematology Care - Fairfield- Site Number : 8400016

    Fairfield, Ohio

  • Spartanburg Regional Medical Center- Site Number : 8400002

    Spartanburg, South Carolina

  • University of Texas - Southwestern Medical Center- Site Number : 8400024

    Dallas, Texas

  • Texas Oncology - San Antonio Medical Center - Research Drive- Site Number : 8400020

    San Antonio, Texas

  • Veterans Affairs Medical Center - Salt Lake City- Site Number : 8400011

    Salt Lake City, Utah

  • Investigational Site Number : 0320008

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320007

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320010

    Córdoba, Argentina

  • Investigational Site Number : 0320009

    Mendoza, Argentina

  • Investigational Site Number : 0320006

    La Plata, Buenos Aires, Argentina

  • Investigational Site Number : 0360007

    Liverpool, New South Wales, Australia

  • Investigational Site Number : 0360004

    Waratah, New South Wales, Australia

  • Investigational Site Number : 0360003

    Wollongong, New South Wales, Australia

  • Investigational Site Number : 0360008

    Adelaide, South Australia, Australia

  • Investigational Site Number : 0360006

    Melbourne, Victoria, Australia

  • Investigational Site Number : 0360009

    Melbourne, Victoria, Australia

  • Investigational Site Number : 0360001

    Richmond, Victoria, Australia

  • Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760004

    Rio de Janeiro, Brazil

  • Clinica São Germano- Site Number : 0760001

    São Paulo, Brazil

  • Núcleo de Oncologia e Hematologia do Ceará- Site Number : 0760006

    Fortaleza, Ceará, Brazil

  • MultiHemo - Recife - Rua Padre Carapuceiro- Site Number : 0760007

    Recife, Pernambuco, Brazil

  • CHN - Complexo Hospitalar de Niterói- Site Number : 0760008

    Niterói, Rio de Janeiro, Brazil

  • Hospital Mae de Deus- Site Number : 0760003

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site Number : 1240001

    Toronto, Ontario, Canada

  • Investigational Site Number : 1240004

    Greenfield Park, Quebec, Canada

  • Investigational Site Number : 1240003

    Montreal, Quebec, Canada

  • Investigational Site Number : 1520001

    Temuco, La Araucanía, Chile

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.